[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBUaROJiUp8dOhsyzYxu2NLYKoJPgOgB8Jy_iavulh_g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Royan Institute",[4],93,false,1,27,6901,2,18,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Infertility",19,{"name":18,"count":19},"Osteoarthritis",4,{"name":21,"count":19},"Polycystic Ovary Syndrome",{"name":23,"count":19},"Amyotrophic Lateral Sclerosis",{"name":25,"count":26},"Infertility, Female",3,{"name":28,"count":26},"Ovarian Hyperstimulation Syndrome",{"name":30,"count":11},"Cerebral Palsy",{"name":32,"count":11},"Female Infertility",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07572071","Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease","2028-08-01","Dopacell",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,72,90,117,135,162,180,205,223,294,320,358,392,417,444,462,488,506,531,549,574,598,616,639,657,684,702,720,738,764,782,800,823,849,867,885,908,933,955,979,997,1023,1041,1059,1084,1126,1168,1196,1223,1256,1279,1303,1326,1348,1373,1391,1416,1434,1452,1475,1499,1524,1542,1565,1583,1607,1625,1651,1669,1696,1744,1762,1785,1809,1831,1854,1876,1899,1922,1943,1965,1987,2009,2032,2053,2079,2100,2122,2147],{"intervention":38,"totalTrials":8,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":64,"PHASE3":66,"PHASE4":68,"NA":70},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":8,"soonestReadout":37},[54],{"nctId":35,"briefTitle":36,"status":55,"phases":56,"primaryCompletion":37,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":62},"RECRUITING",[41],"2030-08-01","2025-08-01",10,[61],"Parkinson Disease (PD)",[38,63],"Immunosuppressive Regimen",{"trials":65,"activeCount":51},[],{"trials":67,"activeCount":51},[],{"trials":69,"activeCount":51},[],{"trials":71,"activeCount":51},[],{"intervention":63,"totalTrials":8,"cells":73},{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":82,"PHASE3":84,"PHASE4":86,"NA":88},{"trials":75,"activeCount":51},[],{"trials":77,"activeCount":8,"soonestReadout":37},[78],{"nctId":35,"briefTitle":36,"status":55,"phases":79,"primaryCompletion":37,"completion":57,"start":58,"enrollment":59,"conditions":80,"interventions":81},[41],[61],[38,63],{"trials":83,"activeCount":51},[],{"trials":85,"activeCount":51},[],{"trials":87,"activeCount":51},[],{"trials":89,"activeCount":51},[],{"intervention":91,"totalTrials":8,"cells":92},"Metformin",{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":115},{"trials":94,"activeCount":51},[],{"trials":96,"activeCount":51},[],{"trials":98,"activeCount":51},[],{"trials":100,"activeCount":51},[],{"trials":102,"activeCount":51},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT01279512","Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)","COMPLETED",[44],"2008-12","2006-12",50,[112],"PCO",[91,114],"Acarbose",{"trials":116,"activeCount":51},[],{"intervention":114,"totalTrials":8,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":133},{"trials":120,"activeCount":51},[],{"trials":122,"activeCount":51},[],{"trials":124,"activeCount":51},[],{"trials":126,"activeCount":51},[],{"trials":128,"activeCount":51},[129],{"nctId":104,"briefTitle":105,"status":106,"phases":130,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":131,"interventions":132},[44],[112],[91,114],{"trials":134,"activeCount":51},[],{"intervention":136,"totalTrials":8,"cells":137},"Lutropin alfa",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":160},{"trials":139,"activeCount":51},[],{"trials":141,"activeCount":51},[],{"trials":143,"activeCount":51},[],{"trials":145,"activeCount":51},[],{"trials":147,"activeCount":51},[148],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT02140515","Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism","UNKNOWN",[44],"2015-12","2016-11","2012-11",90,[15],[136,159],"Follitropin alfa and Lutropin alfa",{"trials":161,"activeCount":51},[],{"intervention":159,"totalTrials":8,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":51},[],{"trials":167,"activeCount":51},[],{"trials":169,"activeCount":51},[],{"trials":171,"activeCount":51},[],{"trials":173,"activeCount":51},[174],{"nctId":149,"briefTitle":150,"status":151,"phases":175,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":176,"interventions":177},[44],[15],[136,159],{"trials":179,"activeCount":51},[],{"intervention":181,"totalTrials":8,"cells":182},"clomiphene citrate with ethinyl esteradiol",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":203},{"trials":184,"activeCount":51},[],{"trials":186,"activeCount":51},[],{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[193],{"nctId":194,"briefTitle":195,"status":106,"phases":196,"primaryCompletion":155,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":201},"NCT01219101","The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination",[44],"2013-02","2011-03",95,[15],[181,202],"clomiphene citrate with plasebo",{"trials":204,"activeCount":51},[],{"intervention":202,"totalTrials":8,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":221},{"trials":208,"activeCount":51},[],{"trials":210,"activeCount":51},[],{"trials":212,"activeCount":51},[],{"trials":214,"activeCount":51},[],{"trials":216,"activeCount":51},[217],{"nctId":194,"briefTitle":195,"status":106,"phases":218,"primaryCompletion":155,"completion":197,"start":198,"enrollment":199,"conditions":219,"interventions":220},[44],[15],[181,202],{"trials":222,"activeCount":51},[],{"intervention":224,"totalTrials":225,"cells":226},"Control",5,{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":265,"PHASE4":290,"NA":292},{"trials":228,"activeCount":51},[],{"trials":230,"activeCount":51},[],{"trials":232,"activeCount":51},[233,244,254],{"nctId":234,"briefTitle":235,"status":106,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT01014104","Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome",[41,42],"2010-08","2010-12","2009-10",218,[28],[243,224],"Methylprednisolone",{"nctId":245,"briefTitle":246,"status":106,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":59,"conditions":251,"interventions":252},"NCT01009567","Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program",[41,42],"2013-06","2013-07","2009-06",[28],[253,224],"Cabergoline",{"nctId":255,"briefTitle":256,"status":106,"phases":257,"primaryCompletion":249,"completion":249,"start":258,"enrollment":259,"conditions":260,"interventions":262},"NCT01120925","Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients",[41,42],"2010-05",30,[261],"Liver Cirrhosis",[263,264,224],"MNC","CD133",{"trials":266,"activeCount":51},[267,278],{"nctId":268,"briefTitle":269,"status":106,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":156,"conditions":274,"interventions":276},"NCT01167751","Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction",[43],"2012-06","2012-07","2008-01",[275],"Myocardial Infarction",[263,277,224],"AC 133",{"nctId":279,"briefTitle":280,"status":106,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT01187654","Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient",[42,43],"2012-09","2012-12","2009-05",80,[275],[288,263,289],"AC133","CONTROL",{"trials":291,"activeCount":51},[],{"trials":293,"activeCount":51},[],{"intervention":263,"totalTrials":26,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":306,"PHASE4":316,"NA":318},{"trials":297,"activeCount":51},[],{"trials":299,"activeCount":51},[],{"trials":301,"activeCount":51},[302],{"nctId":255,"briefTitle":256,"status":106,"phases":303,"primaryCompletion":249,"completion":249,"start":258,"enrollment":259,"conditions":304,"interventions":305},[41,42],[261],[263,264,224],{"trials":307,"activeCount":51},[308,312],{"nctId":268,"briefTitle":269,"status":106,"phases":309,"primaryCompletion":271,"completion":272,"start":273,"enrollment":156,"conditions":310,"interventions":311},[43],[275],[263,277,224],{"nctId":279,"briefTitle":280,"status":106,"phases":313,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":314,"interventions":315},[42,43],[275],[288,263,289],{"trials":317,"activeCount":51},[],{"trials":319,"activeCount":51},[],{"intervention":321,"totalTrials":11,"cells":322},"N-acetyl cysteine",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":354,"NA":356},{"trials":324,"activeCount":51},[],{"trials":326,"activeCount":51},[],{"trials":328,"activeCount":51},[],{"trials":330,"activeCount":51},[331,343],{"nctId":332,"briefTitle":333,"status":151,"phases":334,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":342},"NCT05460858","NAC Effect on Infertile Women With Endometrioma",[43],"2023-09-23","2023-11-30","2021-04-13",140,[32,340,341],"Endometrioma","Stress Oxidative",[321],{"nctId":344,"briefTitle":345,"status":106,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT03862586","NAC Effect on Hox Genes Expressions in RIF",[43],"2017-05-01","2017-07-01","2015-02-01",40,[32],[321,353],"Placebos",{"trials":355,"activeCount":51},[],{"trials":357,"activeCount":51},[],{"intervention":359,"totalTrials":11,"cells":360},"mesenchymal cell transplantation",{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":375,"PHASE3":377,"PHASE4":388,"NA":390},{"trials":362,"activeCount":51},[],{"trials":364,"activeCount":51},[365],{"nctId":366,"briefTitle":367,"status":151,"phases":368,"primaryCompletion":369,"completion":370,"start":197,"enrollment":59,"conditions":371,"interventions":373},"NCT01874015","Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease",[41],"2017-12","2018-02",[372],"Crohn's Disease",[359,374],"mesenchymal cell and fibroblast",{"trials":376,"activeCount":51},[],{"trials":378,"activeCount":51},[379],{"nctId":380,"briefTitle":381,"status":106,"phases":382,"primaryCompletion":198,"completion":383,"start":239,"enrollment":384,"conditions":385,"interventions":387},"NCT01873625","Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis",[42,43],"2011-12",60,[386],"Rheumatoid Arthritis",[359],{"trials":389,"activeCount":51},[],{"trials":391,"activeCount":51},[],{"intervention":393,"totalTrials":8,"cells":394},"PRP",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":413,"NA":415},{"trials":396,"activeCount":51},[],{"trials":398,"activeCount":51},[],{"trials":400,"activeCount":51},[],{"trials":402,"activeCount":51},[403],{"nctId":404,"briefTitle":405,"status":106,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT01926327","The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee",[43],"2014-03","2014-04","2013-01",150,[18],[393],{"trials":414,"activeCount":51},[],{"trials":416,"activeCount":51},[],{"intervention":418,"totalTrials":8,"cells":419},"Intrauterine flushing of follicular fluid with granulosa cells",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":440,"NA":442},{"trials":421,"activeCount":51},[],{"trials":423,"activeCount":51},[],{"trials":425,"activeCount":51},[],{"trials":427,"activeCount":51},[428],{"nctId":429,"briefTitle":430,"status":106,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":338,"conditions":435,"interventions":439},"NCT04077970","Intrauterine Flushing With Follicular Fluid Plus Granulosa Cells",[43],"2022-12-01","2023-01-01","2018-11-01",[436,437,438],"Follicular Fluid","Granulosa Cell","Embryo Implantation",[418],{"trials":441,"activeCount":51},[],{"trials":443,"activeCount":51},[],{"intervention":353,"totalTrials":8,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":458,"NA":460},{"trials":447,"activeCount":51},[],{"trials":449,"activeCount":51},[],{"trials":451,"activeCount":51},[],{"trials":453,"activeCount":51},[454],{"nctId":344,"briefTitle":345,"status":106,"phases":455,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":456,"interventions":457},[43],[32],[321,353],{"trials":459,"activeCount":51},[],{"trials":461,"activeCount":51},[],{"intervention":463,"totalTrials":8,"cells":464},"Microdose GnRh",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":484,"NA":486},{"trials":466,"activeCount":51},[],{"trials":468,"activeCount":51},[],{"trials":470,"activeCount":51},[],{"trials":472,"activeCount":51},[473],{"nctId":474,"briefTitle":475,"status":106,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT01006954","Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle",[43],"2010-01","2010-02","2008-09",200,[15],[463,483],"Flare up",{"trials":485,"activeCount":51},[],{"trials":487,"activeCount":51},[],{"intervention":483,"totalTrials":8,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":502,"NA":504},{"trials":491,"activeCount":51},[],{"trials":493,"activeCount":51},[],{"trials":495,"activeCount":51},[],{"trials":497,"activeCount":51},[498],{"nctId":474,"briefTitle":475,"status":106,"phases":499,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":500,"interventions":501},[43],[15],[463,483],{"trials":503,"activeCount":51},[],{"trials":505,"activeCount":51},[],{"intervention":507,"totalTrials":8,"cells":508},"recombinant hCG",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":527,"NA":529},{"trials":510,"activeCount":51},[],{"trials":512,"activeCount":51},[],{"trials":514,"activeCount":51},[],{"trials":516,"activeCount":51},[517],{"nctId":518,"briefTitle":519,"status":106,"phases":520,"primaryCompletion":282,"completion":248,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT01507376","Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity",[43],"2010-10",180,[524],"In Vitro Fertilization",[507,507,526],"urinary hCG",{"trials":528,"activeCount":51},[],{"trials":530,"activeCount":51},[],{"intervention":526,"totalTrials":8,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":545,"NA":547},{"trials":534,"activeCount":51},[],{"trials":536,"activeCount":51},[],{"trials":538,"activeCount":51},[],{"trials":540,"activeCount":51},[541],{"nctId":518,"briefTitle":519,"status":106,"phases":542,"primaryCompletion":282,"completion":248,"start":521,"enrollment":522,"conditions":543,"interventions":544},[43],[524],[507,507,526],{"trials":546,"activeCount":51},[],{"trials":548,"activeCount":51},[],{"intervention":550,"totalTrials":8,"cells":551},"Strogen",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":570,"NA":572},{"trials":553,"activeCount":51},[],{"trials":555,"activeCount":51},[],{"trials":557,"activeCount":51},[],{"trials":559,"activeCount":51},[560],{"nctId":561,"briefTitle":562,"status":106,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":384,"conditions":567,"interventions":569},"NCT04013438","Luteal Phase Support During Frozen Embryo Transfer Cycle",[43],"2019-01-01","2019-04-30","2017-11-01",[25,568],"Frozen Embryo Transfer",[550,550],{"trials":571,"activeCount":51},[],{"trials":573,"activeCount":51},[],{"intervention":575,"totalTrials":8,"cells":576},"Intra uterine injection of tissue culture medium containing HCG+ET",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":594,"NA":596},{"trials":578,"activeCount":51},[],{"trials":580,"activeCount":51},[],{"trials":582,"activeCount":51},[],{"trials":584,"activeCount":51},[585],{"nctId":586,"briefTitle":587,"status":106,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":522,"conditions":591,"interventions":592},"NCT02825108","Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Embryo Transfer on Pregnancy Outcomes in Frozen Embryo Transfer Cycles.",[43],"2018-12","2015-01",[15],[575,593],"Intra uterine injection of tissue culture medium +ET",{"trials":595,"activeCount":51},[],{"trials":597,"activeCount":51},[],{"intervention":593,"totalTrials":8,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":612,"NA":614},{"trials":601,"activeCount":51},[],{"trials":603,"activeCount":51},[],{"trials":605,"activeCount":51},[],{"trials":607,"activeCount":51},[608],{"nctId":586,"briefTitle":587,"status":106,"phases":609,"primaryCompletion":589,"completion":589,"start":590,"enrollment":522,"conditions":610,"interventions":611},[43],[15],[575,593],{"trials":613,"activeCount":51},[],{"trials":615,"activeCount":51},[],{"intervention":617,"totalTrials":8,"cells":618},"rFSH",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":635,"NA":637},{"trials":620,"activeCount":51},[],{"trials":622,"activeCount":51},[],{"trials":624,"activeCount":51},[],{"trials":626,"activeCount":51},[627],{"nctId":628,"briefTitle":629,"status":106,"phases":630,"primaryCompletion":198,"completion":383,"start":239,"enrollment":631,"conditions":632,"interventions":633},"NCT01509833","Efficacy of Low Dose hCG on Oocyte Maturity in Poor Responder Women Undergoing Intracytoplasmic Sperm Injection",[43],73,[15],[617,634,634],"hCG",{"trials":636,"activeCount":51},[],{"trials":638,"activeCount":51},[],{"intervention":634,"totalTrials":8,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":653,"NA":655},{"trials":642,"activeCount":51},[],{"trials":644,"activeCount":51},[],{"trials":646,"activeCount":51},[],{"trials":648,"activeCount":51},[649],{"nctId":628,"briefTitle":629,"status":106,"phases":650,"primaryCompletion":198,"completion":383,"start":239,"enrollment":631,"conditions":651,"interventions":652},[43],[15],[617,634,634],{"trials":654,"activeCount":51},[],{"trials":656,"activeCount":51},[],{"intervention":658,"totalTrials":8,"cells":659},"frozen Embryo transfer",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":680,"NA":682},{"trials":661,"activeCount":51},[],{"trials":663,"activeCount":51},[],{"trials":665,"activeCount":51},[],{"trials":667,"activeCount":51},[668],{"nctId":669,"briefTitle":670,"status":151,"phases":671,"primaryCompletion":672,"completion":673,"start":282,"enrollment":674,"conditions":675,"interventions":676},"NCT02251925","Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles",[43],"2015-10","2015-11",460,[15],[658,677,678,679],"10,000U hCG","GnRH agonist","administration of 6 mg Estradiol valerate",{"trials":681,"activeCount":51},[],{"trials":683,"activeCount":51},[],{"intervention":677,"totalTrials":8,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":698,"NA":700},{"trials":687,"activeCount":51},[],{"trials":689,"activeCount":51},[],{"trials":691,"activeCount":51},[],{"trials":693,"activeCount":51},[694],{"nctId":669,"briefTitle":670,"status":151,"phases":695,"primaryCompletion":672,"completion":673,"start":282,"enrollment":674,"conditions":696,"interventions":697},[43],[15],[658,677,678,679],{"trials":699,"activeCount":51},[],{"trials":701,"activeCount":51},[],{"intervention":678,"totalTrials":8,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":716,"NA":718},{"trials":705,"activeCount":51},[],{"trials":707,"activeCount":51},[],{"trials":709,"activeCount":51},[],{"trials":711,"activeCount":51},[712],{"nctId":669,"briefTitle":670,"status":151,"phases":713,"primaryCompletion":672,"completion":673,"start":282,"enrollment":674,"conditions":714,"interventions":715},[43],[15],[658,677,678,679],{"trials":717,"activeCount":51},[],{"trials":719,"activeCount":51},[],{"intervention":679,"totalTrials":8,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":734,"NA":736},{"trials":723,"activeCount":51},[],{"trials":725,"activeCount":51},[],{"trials":727,"activeCount":51},[],{"trials":729,"activeCount":51},[730],{"nctId":669,"briefTitle":670,"status":151,"phases":731,"primaryCompletion":672,"completion":673,"start":282,"enrollment":674,"conditions":732,"interventions":733},[43],[15],[658,677,678,679],{"trials":735,"activeCount":51},[],{"trials":737,"activeCount":51},[],{"intervention":739,"totalTrials":8,"cells":740},"oral drug and vaginal placebo",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":760,"NA":762},{"trials":742,"activeCount":51},[],{"trials":744,"activeCount":51},[],{"trials":746,"activeCount":51},[],{"trials":748,"activeCount":51},[749],{"nctId":750,"briefTitle":751,"status":151,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":384,"conditions":756,"interventions":757},"NCT03134157","The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women",[43],"2021-06-14","2021-09-14","2016-08",[15],[739,758,759],"oral drug and oral placebo","Vaginal placebo+ oral placebo",{"trials":761,"activeCount":51},[],{"trials":763,"activeCount":51},[],{"intervention":758,"totalTrials":8,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":778,"NA":780},{"trials":767,"activeCount":51},[],{"trials":769,"activeCount":51},[],{"trials":771,"activeCount":51},[],{"trials":773,"activeCount":51},[774],{"nctId":750,"briefTitle":751,"status":151,"phases":775,"primaryCompletion":753,"completion":754,"start":755,"enrollment":384,"conditions":776,"interventions":777},[43],[15],[739,758,759],{"trials":779,"activeCount":51},[],{"trials":781,"activeCount":51},[],{"intervention":759,"totalTrials":8,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":796,"NA":798},{"trials":785,"activeCount":51},[],{"trials":787,"activeCount":51},[],{"trials":789,"activeCount":51},[],{"trials":791,"activeCount":51},[792],{"nctId":750,"briefTitle":751,"status":151,"phases":793,"primaryCompletion":753,"completion":754,"start":755,"enrollment":384,"conditions":794,"interventions":795},[43],[15],[739,758,759],{"trials":797,"activeCount":51},[],{"trials":799,"activeCount":51},[],{"intervention":801,"totalTrials":8,"cells":802},"Ovulation stimulation",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":819,"NA":821},{"trials":804,"activeCount":51},[],{"trials":806,"activeCount":51},[],{"trials":808,"activeCount":51},[],{"trials":810,"activeCount":51},[811],{"nctId":812,"briefTitle":813,"status":106,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":110,"conditions":817,"interventions":818},"NCT02732808","Dual Ovarian Stimulation in the Same IVF\u002FICSI Cycles for Treatment of Poor Ovarian Responders",[43],"2016-04","2014-09",[15],[801],{"trials":820,"activeCount":51},[],{"trials":822,"activeCount":51},[],{"intervention":824,"totalTrials":8,"cells":825},"Cell therapy protocol 1",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":845,"NA":847},{"trials":827,"activeCount":51},[],{"trials":829,"activeCount":51},[],{"trials":831,"activeCount":51},[],{"trials":833,"activeCount":51},[834],{"nctId":835,"briefTitle":836,"status":151,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":384,"conditions":841,"interventions":843},"NCT04366063","Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome",[42,43],"2020-06-06","2020-12-10","2020-04-05",[842],"Covid-19",[824,844],"Cell therapy protocol 2",{"trials":846,"activeCount":51},[],{"trials":848,"activeCount":51},[],{"intervention":844,"totalTrials":8,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":863,"NA":865},{"trials":852,"activeCount":51},[],{"trials":854,"activeCount":51},[],{"trials":856,"activeCount":51},[],{"trials":858,"activeCount":51},[859],{"nctId":835,"briefTitle":836,"status":151,"phases":860,"primaryCompletion":838,"completion":839,"start":840,"enrollment":384,"conditions":861,"interventions":862},[42,43],[842],[824,844],{"trials":864,"activeCount":51},[],{"trials":866,"activeCount":51},[],{"intervention":277,"totalTrials":8,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":881,"NA":883},{"trials":870,"activeCount":51},[],{"trials":872,"activeCount":51},[],{"trials":874,"activeCount":51},[],{"trials":876,"activeCount":51},[877],{"nctId":268,"briefTitle":269,"status":106,"phases":878,"primaryCompletion":271,"completion":272,"start":273,"enrollment":156,"conditions":879,"interventions":880},[43],[275],[263,277,224],{"trials":882,"activeCount":51},[],{"trials":884,"activeCount":51},[],{"intervention":886,"totalTrials":8,"cells":887},"Asprin",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":904,"NA":906},{"trials":889,"activeCount":51},[],{"trials":891,"activeCount":51},[],{"trials":893,"activeCount":51},[],{"trials":895,"activeCount":51},[896],{"nctId":897,"briefTitle":898,"status":106,"phases":899,"primaryCompletion":282,"completion":900,"start":901,"enrollment":384,"conditions":902,"interventions":903},"NCT01633528","The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy",[43],"2015-02","2012-05",[15],[886],{"trials":905,"activeCount":51},[],{"trials":907,"activeCount":51},[],{"intervention":909,"totalTrials":8,"cells":910},"Percutaneous",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":929,"NA":931},{"trials":912,"activeCount":51},[],{"trials":914,"activeCount":51},[],{"trials":916,"activeCount":51},[],{"trials":918,"activeCount":51},[919],{"nctId":920,"briefTitle":921,"status":151,"phases":922,"primaryCompletion":923,"completion":924,"start":925,"enrollment":384,"conditions":926,"interventions":928},"NCT02448849","Autologous BM-MSC Transplantation in Combination With Platelet Lysate (PL) for Nonunion Treatment",[42,43],"2017-04","2017-08","2015-06",[927],"Bone Fracture",[909],{"trials":930,"activeCount":51},[],{"trials":932,"activeCount":51},[],{"intervention":934,"totalTrials":8,"cells":935},"intrauterine injection of uhCG",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":951,"NA":953},{"trials":937,"activeCount":51},[],{"trials":939,"activeCount":51},[],{"trials":941,"activeCount":51},[],{"trials":943,"activeCount":51},[944],{"nctId":945,"briefTitle":946,"status":106,"phases":947,"primaryCompletion":589,"completion":589,"start":948,"enrollment":522,"conditions":949,"interventions":950},"NCT02355925","Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Cycle Outcomes",[43],"2014-10",[15],[934],{"trials":952,"activeCount":51},[],{"trials":954,"activeCount":51},[],{"intervention":956,"totalTrials":8,"cells":957},"Bahman",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":975,"NA":977},{"trials":959,"activeCount":51},[],{"trials":961,"activeCount":51},[],{"trials":963,"activeCount":51},[],{"trials":965,"activeCount":51},[966],{"nctId":967,"briefTitle":968,"status":151,"phases":969,"primaryCompletion":923,"completion":970,"start":971,"enrollment":480,"conditions":972,"interventions":974},"NCT02998593","The Effect of Combination of Red and White Bahman Retrieved of Iranian Traditional Medicine on Semen Parameters in Idiopathic Oligospermic Men",[43],"2017-06","2016-07",[973],"Infertility, Male",[956],{"trials":976,"activeCount":51},[],{"trials":978,"activeCount":51},[],{"intervention":288,"totalTrials":8,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":993,"NA":995},{"trials":982,"activeCount":51},[],{"trials":984,"activeCount":51},[],{"trials":986,"activeCount":51},[],{"trials":988,"activeCount":51},[989],{"nctId":279,"briefTitle":280,"status":106,"phases":990,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":991,"interventions":992},[42,43],[275],[288,263,289],{"trials":994,"activeCount":51},[],{"trials":996,"activeCount":51},[],{"intervention":998,"totalTrials":8,"cells":999},"Choriomon®",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1019,"NA":1021},{"trials":1001,"activeCount":51},[],{"trials":1003,"activeCount":51},[],{"trials":1005,"activeCount":51},[],{"trials":1007,"activeCount":51},[1008],{"nctId":1009,"briefTitle":1010,"status":151,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":673,"enrollment":1014,"conditions":1015,"interventions":1016},"NCT02798653","Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response",[43],"2019-11","2019-12",210,[15],[998,1017,1018],"Choriomon® injection+Endometrin ®","Endometrin ® vaginal",{"trials":1020,"activeCount":51},[],{"trials":1022,"activeCount":51},[],{"intervention":1017,"totalTrials":8,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":51},[],{"trials":1028,"activeCount":51},[],{"trials":1030,"activeCount":51},[],{"trials":1032,"activeCount":51},[1033],{"nctId":1009,"briefTitle":1010,"status":151,"phases":1034,"primaryCompletion":1012,"completion":1013,"start":673,"enrollment":1014,"conditions":1035,"interventions":1036},[43],[15],[998,1017,1018],{"trials":1038,"activeCount":51},[],{"trials":1040,"activeCount":51},[],{"intervention":1018,"totalTrials":8,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":51},[],{"trials":1046,"activeCount":51},[],{"trials":1048,"activeCount":51},[],{"trials":1050,"activeCount":51},[1051],{"nctId":1009,"briefTitle":1010,"status":151,"phases":1052,"primaryCompletion":1012,"completion":1013,"start":673,"enrollment":1014,"conditions":1053,"interventions":1054},[43],[15],[998,1017,1018],{"trials":1056,"activeCount":51},[],{"trials":1058,"activeCount":51},[],{"intervention":1060,"totalTrials":8,"cells":1061},"Melanocyte transplantation",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1080,"NA":1082},{"trials":1063,"activeCount":51},[],{"trials":1065,"activeCount":51},[],{"trials":1067,"activeCount":51},[],{"trials":1069,"activeCount":51},[1070],{"nctId":1071,"briefTitle":1072,"status":106,"phases":1073,"primaryCompletion":900,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1079},"NCT00631865","Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin",[43],"2015-05","2009-02",300,[1078],"Vitiligo",[1060],{"trials":1081,"activeCount":51},[],{"trials":1083,"activeCount":51},[],{"intervention":1085,"totalTrials":26,"cells":1086},"Intravenous",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1108,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1088,"activeCount":51},[],{"trials":1090,"activeCount":51},[1091,1099],{"nctId":1092,"briefTitle":1093,"status":151,"phases":1094,"primaryCompletion":970,"completion":1095,"start":1074,"enrollment":225,"conditions":1096,"interventions":1098},"NCT02382874","Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)",[41],"2017-10",[1097],"Focal Segmental Glomerulosclerosis",[1085],{"nctId":1100,"briefTitle":1101,"status":106,"phases":1102,"primaryCompletion":153,"completion":1103,"start":408,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT02195323","Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)",[41],"2016-01",7,[1106],"Chronic Kidney Disease",[1085],{"trials":1109,"activeCount":51},[1110],{"nctId":1111,"briefTitle":1112,"status":106,"phases":1113,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":59,"conditions":1117,"interventions":1119},"NCT02801890","Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)",[41,42],"2017-02","2017-03","2015-08",[1118],"Ultra Filtration Failure",[1085],{"trials":1121,"activeCount":51},[],{"trials":1123,"activeCount":51},[],{"trials":1125,"activeCount":51},[],{"intervention":1127,"totalTrials":26,"cells":1128},"mesenchymal stem cell",{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1142,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1130,"activeCount":51},[],{"trials":1132,"activeCount":51},[1133],{"nctId":1134,"briefTitle":1135,"status":106,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1141},"NCT01436058","Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis",[41],"2011-09","2010-09",6,[18],[1127],{"trials":1143,"activeCount":51},[1144,1152],{"nctId":1145,"briefTitle":1146,"status":106,"phases":1147,"primaryCompletion":1148,"completion":672,"start":1149,"enrollment":350,"conditions":1150,"interventions":1151},"NCT01504464","The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis",[42],"2015-09","2012-10",[18],[1127],{"nctId":1153,"briefTitle":1154,"status":106,"phases":1155,"primaryCompletion":1156,"completion":815,"start":1157,"enrollment":350,"conditions":1158,"interventions":1160},"NCT02140528","Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures",[42],"2016-03","2013-08",[1159],"Tibial Fracture",[1161],"Mesenchymal stem cell",{"trials":1163,"activeCount":51},[],{"trials":1165,"activeCount":51},[],{"trials":1167,"activeCount":51},[],{"intervention":264,"totalTrials":11,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1171,"activeCount":51},[],{"trials":1173,"activeCount":51},[],{"trials":1175,"activeCount":51},[1176,1186],{"nctId":1177,"briefTitle":1178,"status":106,"phases":1179,"primaryCompletion":1180,"completion":1075,"start":273,"enrollment":1104,"conditions":1181,"interventions":1184},"NCT00713934","Autologous Bone Marrow Stem Cells in Cirrhosis Patients",[41,42],"2009-01",[1182,1183],"Stem Cell Transplantation","Cirrhosis",[264,1185],"BM-MNC",{"nctId":255,"briefTitle":256,"status":106,"phases":1187,"primaryCompletion":249,"completion":249,"start":258,"enrollment":259,"conditions":1188,"interventions":1189},[41,42],[261],[263,264,224],{"trials":1191,"activeCount":51},[],{"trials":1193,"activeCount":51},[],{"trials":1195,"activeCount":51},[],{"intervention":1185,"totalTrials":11,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1199,"activeCount":51},[],{"trials":1201,"activeCount":51},[],{"trials":1203,"activeCount":51},[1204,1208],{"nctId":1177,"briefTitle":1178,"status":106,"phases":1205,"primaryCompletion":1180,"completion":1075,"start":273,"enrollment":1104,"conditions":1206,"interventions":1207},[41,42],[1182,1183],[264,1185],{"nctId":1209,"briefTitle":1210,"status":106,"phases":1211,"primaryCompletion":239,"completion":477,"start":273,"enrollment":1212,"conditions":1213,"interventions":1216},"NCT00677404","Autologous Transplantation of Bone Marrow Mononuclear Cell (BM-MNC) With and Without Granulocyte-Colony Stimulation Factor (G-CSF) for Treatment of Chronic Lower Limb Ischemic Patients",[41,42],20,[1214,1215],"Peripheral Vascular Diseases","Ischemia",[1185],{"trials":1218,"activeCount":51},[],{"trials":1220,"activeCount":51},[],{"trials":1222,"activeCount":51},[],{"intervention":1224,"totalTrials":11,"cells":1225},"Amniotic Membrane Extract Eye Drop",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1240,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1227,"activeCount":51},[],{"trials":1229,"activeCount":51},[1230],{"nctId":1231,"briefTitle":1232,"status":106,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":59,"conditions":1237,"interventions":1239},"NCT02649621","The Improvement of Limbal Stem Cell Deficiency (LSCD) in Unilateral Stem Cell Damage by Amniotic Membrane Extract Eye Drop (AMEED)",[41],"2012-03","2012-08","2011-08",[1238],"Limbal Stem Cell Deficiency (LSCD)",[1224],{"trials":1241,"activeCount":51},[1242],{"nctId":1243,"briefTitle":1244,"status":106,"phases":1245,"primaryCompletion":1074,"completion":673,"start":1246,"enrollment":1212,"conditions":1247,"interventions":1249},"NCT02746848","Utilization of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Healing",[41,42],"2014-06",[1248],"Cornea Injury",[1224],{"trials":1251,"activeCount":51},[],{"trials":1253,"activeCount":51},[],{"trials":1255,"activeCount":51},[],{"intervention":1257,"totalTrials":8,"cells":1258},"stem cell intrathecal",{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1260,"activeCount":51},[],{"trials":1262,"activeCount":51},[],{"trials":1264,"activeCount":51},[1265],{"nctId":1266,"briefTitle":1267,"status":106,"phases":1268,"primaryCompletion":408,"completion":408,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1272},"NCT01763255","Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy",[41,42],"2012-04",8,[30],[1257],{"trials":1274,"activeCount":51},[],{"trials":1276,"activeCount":51},[],{"trials":1278,"activeCount":51},[],{"intervention":1280,"totalTrials":8,"cells":1281},"oral administration of ginger",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1283,"activeCount":51},[],{"trials":1285,"activeCount":51},[],{"trials":1287,"activeCount":51},[1288],{"nctId":1289,"briefTitle":1290,"status":106,"phases":1291,"primaryCompletion":1138,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1296},"NCT02032251","Reduction of Sperm DNA Fragmentation by Oral Ginger",[42],"2010-11","2009-12",71,[15],[1280],{"trials":1298,"activeCount":51},[],{"trials":1300,"activeCount":51},[],{"trials":1302,"activeCount":51},[],{"intervention":1304,"totalTrials":8,"cells":1305},"paraurethral",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1307,"activeCount":51},[],{"trials":1309,"activeCount":51},[],{"trials":1311,"activeCount":51},[1312],{"nctId":1313,"briefTitle":1314,"status":106,"phases":1315,"primaryCompletion":153,"completion":153,"start":1316,"enrollment":1212,"conditions":1317,"interventions":1319},"NCT02156934","Paraurethral Transplantation of Autologous Muscle Derived Stem Cells for Treatment of Stress Incontinency",[42],"2014-01",[1318],"Stress Urine Incontinency",[1304],{"trials":1321,"activeCount":51},[],{"trials":1323,"activeCount":51},[],{"trials":1325,"activeCount":51},[],{"intervention":1327,"totalTrials":8,"cells":1328},"Sildenafil vaginal suppositories",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1330,"activeCount":51},[],{"trials":1332,"activeCount":51},[],{"trials":1334,"activeCount":51},[1335],{"nctId":1336,"briefTitle":1337,"status":151,"phases":1338,"primaryCompletion":924,"completion":1339,"start":900,"enrollment":384,"conditions":1340,"interventions":1341},"NCT03192709","Sildenafil and Outcome of IVF\u002FICSI Cycles",[41,42],"2017-09",[25],[1327],{"trials":1343,"activeCount":51},[],{"trials":1345,"activeCount":51},[],{"trials":1347,"activeCount":51},[],{"intervention":1349,"totalTrials":8,"cells":1350},"low dose human chorionic gonadotropin",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1352,"activeCount":51},[],{"trials":1354,"activeCount":51},[],{"trials":1356,"activeCount":51},[1357],{"nctId":1358,"briefTitle":1359,"status":106,"phases":1360,"primaryCompletion":237,"completion":238,"start":1361,"enrollment":59,"conditions":1362,"interventions":1365},"NCT00947713","Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome",[41,42],"2009-08",[1363,1364],"Endocrine System Diseases","Gonadal Disorders",[1349,1366],"Clomiphen citrate plus HMG",{"trials":1368,"activeCount":51},[],{"trials":1370,"activeCount":51},[],{"trials":1372,"activeCount":51},[],{"intervention":1366,"totalTrials":8,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1376,"activeCount":51},[],{"trials":1378,"activeCount":51},[],{"trials":1380,"activeCount":51},[1381],{"nctId":1358,"briefTitle":1359,"status":106,"phases":1382,"primaryCompletion":237,"completion":238,"start":1361,"enrollment":59,"conditions":1383,"interventions":1384},[41,42],[1363,1364],[1349,1366],{"trials":1386,"activeCount":51},[],{"trials":1388,"activeCount":51},[],{"trials":1390,"activeCount":51},[],{"intervention":1392,"totalTrials":8,"cells":1393},"Intraovarian injection of Adipose derived Stromal cells",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1395,"activeCount":51},[],{"trials":1397,"activeCount":51},[],{"trials":1399,"activeCount":51},[1400],{"nctId":1401,"briefTitle":1402,"status":151,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":925,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT02603744","Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)",[41,42],"2018-06","2018-11",9,[1408],"Premature Ovarian Failure",[1392],{"trials":1411,"activeCount":51},[],{"trials":1413,"activeCount":51},[],{"trials":1415,"activeCount":51},[],{"intervention":243,"totalTrials":8,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1419,"activeCount":51},[],{"trials":1421,"activeCount":51},[],{"trials":1423,"activeCount":51},[1424],{"nctId":234,"briefTitle":235,"status":106,"phases":1425,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1426,"interventions":1427},[41,42],[28],[243,224],{"trials":1429,"activeCount":51},[],{"trials":1431,"activeCount":51},[],{"trials":1433,"activeCount":51},[],{"intervention":253,"totalTrials":8,"cells":1435},{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1437,"activeCount":51},[],{"trials":1439,"activeCount":51},[],{"trials":1441,"activeCount":51},[1442],{"nctId":245,"briefTitle":246,"status":106,"phases":1443,"primaryCompletion":248,"completion":249,"start":250,"enrollment":59,"conditions":1444,"interventions":1445},[41,42],[28],[253,224],{"trials":1447,"activeCount":51},[],{"trials":1449,"activeCount":51},[],{"trials":1451,"activeCount":51},[],{"intervention":1453,"totalTrials":8,"cells":1454},"Platelet Gel",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1456,"activeCount":51},[],{"trials":1458,"activeCount":51},[],{"trials":1460,"activeCount":51},[1461],{"nctId":1462,"briefTitle":1463,"status":106,"phases":1464,"primaryCompletion":407,"completion":408,"start":1465,"enrollment":259,"conditions":1466,"interventions":1468},"NCT02134132","Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers",[41,42],"2012-01",[1467],"Diabetic Foot Ulcers",[1453],{"trials":1470,"activeCount":51},[],{"trials":1472,"activeCount":51},[],{"trials":1474,"activeCount":51},[],{"intervention":1476,"totalTrials":8,"cells":1477},"Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles",{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1493,"PHASE4":1495,"NA":1497},{"trials":1479,"activeCount":51},[],{"trials":1481,"activeCount":51},[],{"trials":1483,"activeCount":51},[1484],{"nctId":1485,"briefTitle":1486,"status":151,"phases":1487,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":59,"conditions":1491,"interventions":1492},"NCT06202547","Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure",[41,42],"2024-09-20","2025-02-18","2023-02-20",[1408],[1476],{"trials":1494,"activeCount":51},[],{"trials":1496,"activeCount":51},[],{"trials":1498,"activeCount":51},[],{"intervention":1500,"totalTrials":8,"cells":1501},"Intracoronary",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1503,"activeCount":51},[],{"trials":1505,"activeCount":51},[],{"trials":1507,"activeCount":51},[1508],{"nctId":1509,"briefTitle":1510,"status":151,"phases":1511,"primaryCompletion":1512,"completion":369,"start":1513,"enrollment":110,"conditions":1514,"interventions":1516},"NCT01758406","Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart Failure",[42],"2017-11","2013-12",[1515],"Heart Failure",[1500,1517],"Intracoronary injection of Placebo",{"trials":1519,"activeCount":51},[],{"trials":1521,"activeCount":51},[],{"trials":1523,"activeCount":51},[],{"intervention":1517,"totalTrials":8,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1527,"activeCount":51},[],{"trials":1529,"activeCount":51},[],{"trials":1531,"activeCount":51},[1532],{"nctId":1509,"briefTitle":1510,"status":151,"phases":1533,"primaryCompletion":1512,"completion":369,"start":1513,"enrollment":110,"conditions":1534,"interventions":1535},[42],[1515],[1500,1517],{"trials":1537,"activeCount":51},[],{"trials":1539,"activeCount":51},[],{"trials":1541,"activeCount":51},[],{"intervention":1543,"totalTrials":8,"cells":1544},"4times",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1546,"activeCount":51},[],{"trials":1548,"activeCount":51},[],{"trials":1550,"activeCount":51},[1551],{"nctId":1552,"briefTitle":1553,"status":106,"phases":1554,"primaryCompletion":1269,"completion":901,"start":1138,"enrollment":1212,"conditions":1555,"interventions":1557},"NCT01480414","Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb",[41,42],[1556],"Ischemic Ulcer",[1543,1558],"stem cell transplantation",{"trials":1560,"activeCount":51},[],{"trials":1562,"activeCount":51},[],{"trials":1564,"activeCount":51},[],{"intervention":1558,"totalTrials":8,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":51},[],{"trials":1570,"activeCount":51},[],{"trials":1572,"activeCount":51},[1573],{"nctId":1552,"briefTitle":1553,"status":106,"phases":1574,"primaryCompletion":1269,"completion":901,"start":1138,"enrollment":1212,"conditions":1575,"interventions":1576},[41,42],[1556],[1543,1558],{"trials":1578,"activeCount":51},[],{"trials":1580,"activeCount":51},[],{"trials":1582,"activeCount":51},[],{"intervention":1584,"totalTrials":8,"cells":1585},"intravenous injection of mesenchymal stem cells",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1587,"activeCount":51},[],{"trials":1589,"activeCount":51},[],{"trials":1591,"activeCount":51},[1592],{"nctId":1593,"briefTitle":1594,"status":106,"phases":1595,"primaryCompletion":407,"completion":408,"start":383,"enrollment":1596,"conditions":1597,"interventions":1599},"NCT01377870","Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis",[41,42],22,[1598],"Multiple Sclerosis",[1584,1600],"injection of cell free media",{"trials":1602,"activeCount":51},[],{"trials":1604,"activeCount":51},[],{"trials":1606,"activeCount":51},[],{"intervention":1600,"totalTrials":8,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1610,"activeCount":51},[],{"trials":1612,"activeCount":51},[],{"trials":1614,"activeCount":51},[1615],{"nctId":1593,"briefTitle":1594,"status":106,"phases":1616,"primaryCompletion":407,"completion":408,"start":383,"enrollment":1596,"conditions":1617,"interventions":1618},[41,42],[1598],[1584,1600],{"trials":1620,"activeCount":51},[],{"trials":1622,"activeCount":51},[],{"trials":1624,"activeCount":51},[],{"intervention":1626,"totalTrials":8,"cells":1627},"Fibroblast",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1629,"activeCount":51},[],{"trials":1631,"activeCount":51},[],{"trials":1633,"activeCount":51},[1634],{"nctId":1635,"briefTitle":1636,"status":106,"phases":1637,"primaryCompletion":1148,"completion":673,"start":479,"enrollment":384,"conditions":1638,"interventions":1643},"NCT01115634","Autologous Fibroblast Transplantation in Facial Deformities",[42],[1639,1640,1641,1642],"Nasolabial Folds","Glabellar Crease","Deep Wrinkles of the Forehead","Acne Scars",[1626,1644],"fibroblast and gel",{"trials":1646,"activeCount":51},[],{"trials":1648,"activeCount":51},[],{"trials":1650,"activeCount":51},[],{"intervention":1644,"totalTrials":8,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1654,"activeCount":51},[],{"trials":1656,"activeCount":51},[],{"trials":1658,"activeCount":51},[1659],{"nctId":1635,"briefTitle":1636,"status":106,"phases":1660,"primaryCompletion":1148,"completion":673,"start":479,"enrollment":384,"conditions":1661,"interventions":1662},[42],[1639,1640,1641,1642],[1626,1644],{"trials":1664,"activeCount":51},[],{"trials":1666,"activeCount":51},[],{"trials":1668,"activeCount":51},[],{"intervention":1670,"totalTrials":8,"cells":1671},"Intravenous Injection of autologous mesenchymal stem cells",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1673,"activeCount":51},[],{"trials":1675,"activeCount":51},[],{"trials":1677,"activeCount":51},[1678],{"nctId":1679,"briefTitle":1680,"status":151,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1212,"conditions":1685,"interventions":1689},"NCT04078308","Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients",[41,42],"2019-09-26","2020-04-01","2015-07-06",[1686,1687,1688],"Diabetes Mellitus","Diabetes Mellitus, Type 1","Diabetes Mellitus, Insulin-Dependent",[1670],{"trials":1691,"activeCount":51},[],{"trials":1693,"activeCount":51},[],{"trials":1695,"activeCount":51},[],{"intervention":1697,"totalTrials":19,"cells":1698},"cell",{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1736,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1700,"activeCount":51},[],{"trials":1702,"activeCount":51},[1703,1712,1720,1729],{"nctId":1704,"briefTitle":1705,"status":106,"phases":1706,"primaryCompletion":198,"completion":1707,"start":1708,"enrollment":1139,"conditions":1709,"interventions":1711},"NCT01206179","Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell",[41],"2011-05","2009-03",[1710],"Nonunion Fractures",[1697],{"nctId":1713,"briefTitle":1714,"status":106,"phases":1715,"primaryCompletion":1716,"completion":383,"start":239,"enrollment":1139,"conditions":1717,"interventions":1719},"NCT01207193","Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation",[41],"2011-10",[1718],"Bone Cyst",[1697],{"nctId":1721,"briefTitle":1722,"status":106,"phases":1723,"primaryCompletion":249,"completion":249,"start":1724,"enrollment":26,"conditions":1725,"interventions":1727},"NCT01454336","Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone",[41],"2010-06",[1726],"Liver Fibrosis",[1728],"Cell",{"nctId":1730,"briefTitle":1731,"status":106,"phases":1732,"primaryCompletion":1157,"completion":1157,"start":198,"enrollment":1139,"conditions":1733,"interventions":1735},"NCT01500811","Autologous Chondrocyte Intra-articular Implantation in Patients With Severe Hip Osteoarthritis",[41],[1734],"Hip Osteoarthritis",[1697],{"trials":1737,"activeCount":51},[],{"trials":1739,"activeCount":51},[],{"trials":1741,"activeCount":51},[],{"trials":1743,"activeCount":51},[],{"intervention":374,"totalTrials":8,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1747,"activeCount":51},[],{"trials":1749,"activeCount":51},[1750],{"nctId":366,"briefTitle":367,"status":151,"phases":1751,"primaryCompletion":369,"completion":370,"start":197,"enrollment":59,"conditions":1752,"interventions":1753},[41],[372],[359,374],{"trials":1755,"activeCount":51},[],{"trials":1757,"activeCount":51},[],{"trials":1759,"activeCount":51},[],{"trials":1761,"activeCount":51},[],{"intervention":1763,"totalTrials":8,"cells":1764},"cell and RPR",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1766,"activeCount":51},[],{"trials":1768,"activeCount":51},[1769],{"nctId":1770,"briefTitle":1771,"status":106,"phases":1772,"primaryCompletion":1513,"completion":1513,"start":1773,"enrollment":1139,"conditions":1774,"interventions":1776},"NCT01210950","Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation",[41],"2009-09",[1775],"Leg Length Inequality",[1763],{"trials":1778,"activeCount":51},[],{"trials":1780,"activeCount":51},[],{"trials":1782,"activeCount":51},[],{"trials":1784,"activeCount":51},[],{"intervention":1786,"totalTrials":8,"cells":1787},"Intramuscular",{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1789,"activeCount":51},[],{"trials":1791,"activeCount":51},[1792],{"nctId":1793,"briefTitle":1794,"status":151,"phases":1795,"primaryCompletion":1512,"completion":369,"start":1796,"enrollment":1797,"conditions":1798,"interventions":1800},"NCT02208713","Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)",[41],"2014-05",21,[1799],"Dystrophy",[1786],{"trials":1802,"activeCount":51},[],{"trials":1804,"activeCount":51},[],{"trials":1806,"activeCount":51},[],{"trials":1808,"activeCount":51},[],{"intervention":1810,"totalTrials":8,"cells":1811},"intrathecal",{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1813,"activeCount":51},[],{"trials":1815,"activeCount":51},[1816],{"nctId":1817,"briefTitle":1818,"status":106,"phases":1819,"primaryCompletion":948,"completion":1820,"start":1157,"enrollment":1270,"conditions":1821,"interventions":1822},"NCT01771640","Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS",[41],"2014-12",[23],[1810],{"trials":1824,"activeCount":51},[],{"trials":1826,"activeCount":51},[],{"trials":1828,"activeCount":51},[],{"trials":1830,"activeCount":51},[],{"intervention":1832,"totalTrials":8,"cells":1833},"Intravenous injection autologous mesenchymal stem cells",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1835,"activeCount":51},[],{"trials":1837,"activeCount":51},[1838],{"nctId":1839,"briefTitle":1840,"status":106,"phases":1841,"primaryCompletion":153,"completion":1103,"start":407,"enrollment":1139,"conditions":1842,"interventions":1845},"NCT02166489","Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease",[41],[1843,1844],"Chronic Renal Failure","Polycystic Kidney Disease",[1832],{"trials":1847,"activeCount":51},[],{"trials":1849,"activeCount":51},[],{"trials":1851,"activeCount":51},[],{"trials":1853,"activeCount":51},[],{"intervention":1855,"totalTrials":8,"cells":1856},"CD133+ cells",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1858,"activeCount":51},[],{"trials":1860,"activeCount":51},[1861],{"nctId":1862,"briefTitle":1863,"status":106,"phases":1864,"primaryCompletion":248,"completion":248,"start":1361,"enrollment":59,"conditions":1865,"interventions":1867},"NCT01198080","Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head",[41],[1866],"Osteonecrosis",[1855],{"trials":1869,"activeCount":51},[],{"trials":1871,"activeCount":51},[],{"trials":1873,"activeCount":51},[],{"trials":1875,"activeCount":51},[],{"intervention":1877,"totalTrials":8,"cells":1878},"Cell transplantation",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1880,"activeCount":51},[],{"trials":1882,"activeCount":51},[1883],{"nctId":1884,"briefTitle":1885,"status":106,"phases":1886,"primaryCompletion":282,"completion":249,"start":1887,"enrollment":1139,"conditions":1888,"interventions":1890},"NCT01908088","Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa",[41],"2010-07",[1889],"Epidermolysis Bullosa With Mitten Hands",[1877],{"trials":1892,"activeCount":51},[],{"trials":1894,"activeCount":51},[],{"trials":1896,"activeCount":51},[],{"trials":1898,"activeCount":51},[],{"intervention":1900,"totalTrials":8,"cells":1901},"paraurethral injection of MDCs",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1903,"activeCount":51},[],{"trials":1905,"activeCount":51},[1906],{"nctId":1907,"briefTitle":1908,"status":106,"phases":1909,"primaryCompletion":1910,"completion":816,"start":409,"enrollment":59,"conditions":1911,"interventions":1913},"NCT01963455","Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency",[41],"2014-08",[1912],"Stress Incontinency",[1900],{"trials":1915,"activeCount":51},[],{"trials":1917,"activeCount":51},[],{"trials":1919,"activeCount":51},[],{"trials":1921,"activeCount":51},[],{"intervention":1923,"totalTrials":8,"cells":1924},"Mesenchymal",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1926,"activeCount":51},[],{"trials":1928,"activeCount":51},[1929],{"nctId":1930,"briefTitle":1931,"status":106,"phases":1932,"primaryCompletion":1887,"completion":1292,"start":1361,"enrollment":1139,"conditions":1933,"interventions":1934},"NCT01207661","Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint",[41],[18],[1923],{"trials":1936,"activeCount":51},[],{"trials":1938,"activeCount":51},[],{"trials":1940,"activeCount":51},[],{"trials":1942,"activeCount":51},[],{"intervention":1944,"totalTrials":8,"cells":1945},"CD133 stem cell",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1947,"activeCount":51},[],{"trials":1949,"activeCount":51},[1950],{"nctId":1951,"briefTitle":1952,"status":106,"phases":1953,"primaryCompletion":1269,"completion":901,"start":1716,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT01404663","Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy",[41],12,[30],[1944],{"trials":1958,"activeCount":51},[],{"trials":1960,"activeCount":51},[],{"trials":1962,"activeCount":51},[],{"trials":1964,"activeCount":51},[],{"intervention":1966,"totalTrials":8,"cells":1967},"Intraventricular",{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1979,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1969,"activeCount":51},[],{"trials":1971,"activeCount":51},[1972],{"nctId":1973,"briefTitle":1974,"status":1975,"phases":1976,"primaryCompletion":1115,"start":407,"enrollment":51,"conditions":1977,"interventions":1978},"NCT01759784","Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS","WITHDRAWN",[41],[23],[1966],{"trials":1980,"activeCount":51},[],{"trials":1982,"activeCount":51},[],{"trials":1984,"activeCount":51},[],{"trials":1986,"activeCount":51},[],{"intervention":1988,"totalTrials":8,"cells":1989},"BM-MSC transplantation",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1991,"activeCount":51},[],{"trials":1993,"activeCount":51},[1994],{"nctId":1995,"briefTitle":1996,"status":151,"phases":1997,"primaryCompletion":1405,"completion":589,"start":673,"enrollment":259,"conditions":1998,"interventions":2000},"NCT02646007","Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease",[41],[1999],"Kienböck's Disease",[1988],{"trials":2002,"activeCount":51},[],{"trials":2004,"activeCount":51},[],{"trials":2006,"activeCount":51},[],{"trials":2008,"activeCount":51},[],{"intervention":2010,"totalTrials":8,"cells":2011},"Bone marrow derived mesenchymal stem cells",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2013,"activeCount":51},[],{"trials":2015,"activeCount":51},[2016],{"nctId":2017,"briefTitle":2018,"status":106,"phases":2019,"primaryCompletion":1887,"completion":238,"start":2020,"enrollment":1139,"conditions":2021,"interventions":2023},"NCT00850187","Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage",[41],"2008-08",[2022],"Knee Osteoarthritis",[2010],{"trials":2025,"activeCount":51},[],{"trials":2027,"activeCount":51},[],{"trials":2029,"activeCount":51},[],{"trials":2031,"activeCount":51},[],{"intervention":2033,"totalTrials":8,"cells":2034},"intra venous injection of stem cell",{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2036,"activeCount":51},[],{"trials":2038,"activeCount":51},[2039],{"nctId":2040,"briefTitle":2041,"status":106,"phases":2042,"primaryCompletion":1316,"completion":407,"start":409,"enrollment":1139,"conditions":2043,"interventions":2044},"NCT01759797","Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS",[41],[23],[2033],{"trials":2046,"activeCount":51},[],{"trials":2048,"activeCount":51},[],{"trials":2050,"activeCount":51},[],{"trials":2052,"activeCount":51},[],{"intervention":2054,"totalTrials":8,"cells":2055},"NK cell therapy",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2057,"activeCount":51},[],{"trials":2059,"activeCount":51},[2060],{"nctId":2061,"briefTitle":2062,"status":151,"phases":2063,"primaryCompletion":2064,"completion":2065,"start":2066,"enrollment":225,"conditions":2067,"interventions":2070},"NCT05108012","Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients",[41],"2021-11","2022-04","2021-08-01",[2068,2069],"Glioblastoma Multiform","Recurrent Glioblastoma",[2054],{"trials":2072,"activeCount":51},[],{"trials":2074,"activeCount":51},[],{"trials":2076,"activeCount":51},[],{"trials":2078,"activeCount":51},[],{"intervention":2080,"totalTrials":8,"cells":2081},"mesenchymal stem cells",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2083,"activeCount":51},[],{"trials":2085,"activeCount":51},[2086],{"nctId":2087,"briefTitle":2088,"status":106,"phases":2089,"primaryCompletion":1115,"completion":923,"start":816,"enrollment":16,"conditions":2090,"interventions":2091},"NCT02492516","Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS",[41],[23],[2080],{"trials":2093,"activeCount":51},[],{"trials":2095,"activeCount":51},[],{"trials":2097,"activeCount":51},[],{"trials":2099,"activeCount":51},[],{"intervention":2101,"totalTrials":8,"cells":2102},"stem cell",{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2104,"activeCount":51},[],{"trials":2106,"activeCount":51},[2107],{"nctId":2108,"briefTitle":2109,"status":106,"phases":2110,"primaryCompletion":2111,"completion":198,"start":1724,"enrollment":1139,"conditions":2112,"interventions":2113},"NCT01499056","Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint",[41],"2011-02",[1734],[2101],{"trials":2115,"activeCount":51},[],{"trials":2117,"activeCount":51},[],{"trials":2119,"activeCount":51},[],{"trials":2121,"activeCount":51},[],{"intervention":2123,"totalTrials":8,"cells":2124},"L-carnitine 1000 Mg",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2126,"activeCount":51},[],{"trials":2128,"activeCount":51},[],{"trials":2130,"activeCount":51},[],{"trials":2132,"activeCount":51},[],{"trials":2134,"activeCount":51},[],{"trials":2136,"activeCount":51},[2137],{"nctId":2138,"briefTitle":2139,"status":106,"phases":2140,"primaryCompletion":2141,"completion":2142,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2146},"NCT04672720","L-carnitine and COH in PCOS Women Undergoing IVF\u002FICSI Cycles",[45],"2022-12-29","2023-02-28","2020-03-01",110,[21],[2123],{"intervention":2148,"totalTrials":8,"cells":2149},"The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2151,"activeCount":51},[],{"trials":2153,"activeCount":51},[],{"trials":2155,"activeCount":51},[],{"trials":2157,"activeCount":51},[],{"trials":2159,"activeCount":51},[],{"trials":2161,"activeCount":51},[2162],{"nctId":2163,"briefTitle":2164,"status":106,"phases":2165,"primaryCompletion":2166,"completion":2167,"start":2168,"enrollment":480,"conditions":2169,"interventions":2170},"NCT04855383","Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles",[45],"2022-08-22","2023-06-20","2020-07-01",[438],[2148]]